Has my stock been accused of fraud?Join over 160k users who know.

Ticker Price Change($) Change(%) Shares Volume Prev Close Open Gain($) Gain(%)
Ticker Status Jurisdiction Filing Date CP Start CP End CP Loss Deadline
Ticker Case Name Status CP Start CP End Deadline Settlement Amt
Ticker Name Date Analyst Firm Up/Down Target ($) Rating Change Rating Current

News

Piper Sandler Reiterates Overweight on CME Gr, Maintains $225 Price Target

Author: Benzinga Newsdesk | August 20, 2024 11:02am
Piper Sandler analyst Patrick Moley reiterates CME Gr (NASDAQ:CME) with a Overweight and maintains $225 price target.

Posted In: CME

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION

CORE Finalist